BFC Planning’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.75K Hold
72
– – ﹤0.01% 2712
2026
Q2
$6.13K Buy
72
+9
+14% +$646 ﹤0.01% 2600
2026
Q1
$4.15K Sell
63
-6
-9% -$381 ﹤0.01% 2379
2025
Q4
$4.38K Buy
69
+16
+30% +$995 ﹤0.01% 2399
2025
Q3
$2.91K Buy
53
+12
+29% +$494 ﹤0.01% 2365
2025
Q2
$1.36K Hold
41
– – ﹤0.01% 2389
2025
Q1
$1.65K Buy
41
+14
+52% +$643 ﹤0.01% 2343
2024
Q4
$1.27K Sell
27
-8
-23% -$415 ﹤0.01% 2368
2024
Q3
$1.85K Buy
+35
New +$1.95K ﹤0.01% 2297

Other funds holding CYTK

BFC Planning's CYTK Position: Q3 2026 in Review

BFC Planning held its Cytokinetics (CYTK) position steady in Q3 2026 at 72 shares worth $4.75K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

BFC Planning first reported a position in CYTK in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.13K in Q2 2026. 354 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • BFC Planning held 72 shares of Cytokinetics worth $4.75K as of Q3 2026.
  • BFC Planning left its Cytokinetics share count unchanged in Q3 2026.
  • Cytokinetics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2712 holding.
  • BFC Planning first reported a position in Cytokinetics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Cytokinetics position peaked at $6.13K in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.